Group 1: Report Industry Investment Rating - Not provided in the content Group 2: Core Viewpoints of the Report - The direct and main impact of resuming taxation is to increase the yield of new bonds and slightly lower the yield of old bonds. The pricing of new bonds depends largely on the investor structure, while the pricing of old bonds depends on investors' expectations of new bond yields [2][9]. - For 10Y treasury bonds, the current yield on August 1st is 1.71%. Bank self - operating investors with a 6% VAT rate have an equivalent yield of 1.83% after tax resumption, a 12bp increase; asset management accounts with a 3% tax rate have an equivalent yield of 1.77%, a 6bp increase [2][9]. - The reasonable spread range between new and old bonds is (6bp, 12bp). When the spread is below 6bp, all investors tend to sell new bonds and buy old bonds; when it is above 12bp, all investors have the motivation to buy new bonds and sell old bonds; when it is between 6bp and 12bp, 6% - tax - rate investors tend to sell new bonds and buy old bonds, while 3% - tax - rate investors tend to buy new bonds and sell old bonds [2][10]. - If there are only 3% - or 6% - tax - rate investors, the yield increase is borne by new bonds, and old bonds remain at the current level. If both types of investors exist, the increase in new bond yields is hard to satisfy both, and 6% - tax - rate investors' tendency to buy old bonds will push old bond yields down [3][13]. - Old bond yields below 1.71% are pushed by 6% - tax - rate investors. Only when their proportion is moderate can they push old bond yields down from 1.71%. The theoretical limit of old bond yields is new bond yields - 12bp, and the actual downward range of old bond yields is very limited [4][15]. Group 3: Summary According to the Directory 1. How to Price New and Old Bonds after Resuming Taxation? - On August 1st, 2025, the Ministry of Finance and the State Taxation Administration announced that starting from August 8th, 2025, VAT on the interest income of newly issued national, local government, and financial bonds will be resumed [1][9]. - Taking 10Y treasury bonds as an example, different tax - rate investors have different equivalent yields after tax resumption. Bank self - operating investors with a 6% VAT rate have an equivalent yield of 1.83%, a 12bp increase; asset management accounts with a 3% tax rate have an equivalent yield of 1.77%, a 6bp increase [2][9]. - Four scenarios are established to study the dynamic relationship between new and old bond yields. In scenarios where only one type of tax - rate investor exists, old bond yields remain unchanged. In scenarios where both types exist, 6% - tax - rate investors' behavior may push old bond yields down [12][14]. - The theoretical limit of old bond yields is new bond yields - 12bp, and the actual downward range of old bond yields is limited, as shown in the graph of the relationship between new and old bond yields [15][16].

2025 年 8 月 4 日 行业研究 如何看待股债跷跷板和 8 月流动性？ ——流动性观察第 114 期 银行业 买入（维持） 作者 分析师：王一峰 执业证书编号：S0930519050002 010-57378038 wangyf@ebscn.com 分析师：赵晨阳 执业证书编号：S0930524070005 010-57378030 zhaochenyang@ebscn.com 行业与沪深 300 指数对比图 资料来源：Wind 相关研报 6 月金融数据前瞻——流动性观察第 113 期 7 月流动性：自发宽松——流动性观察第 112 期 5 月金融数据前瞻——流动性观察第 111 期 6 月流动性展望——流动性观察第 110 期 4 月金融数据前瞻及 5 月流动性展望——流动性观 察第 109 期 3 月金融数据前瞻及 4 月流动性展望——流动性观 察第 108 期 2 月金融数据前瞻及 3 月流动性展望——流动性观 察第 107 期 1 月金融数据前瞻及 2 月流动性展望——流动性观 察第 106 期 12 月金融数据前瞻及 1 月流动性展望——流动性 观察第 105 期 11 月金融数据前瞻及 12 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Viewpoints - The company has a complete industrial chain in the silicon-based new materials sector, covering upstream silicon mining, organic silicon monomer synthesis, and downstream product manufacturing, making it the most comprehensive player in the domestic organic silicon industry [2]. - The company has established a fully integrated development model in crop protection, offering a complete range of herbicides and other agricultural products, and is a leader in global herbicide varieties [3]. - The company is accelerating its globalization efforts, establishing multiple overseas production bases and expanding its marketing network to over 130 countries and regions [3]. Summary by Sections Company Overview - The company has a registered capital of 15 million yuan for its new subsidiary, Zhejiang Xin'an Yushi Silicon Technology Co., Ltd., which focuses on synthetic materials and high-quality synthetic rubber sales [1]. Financial Forecasts - The company’s projected net profits for 2025, 2026, and 2027 are 283 million yuan (down 29.7%), 472 million yuan (down 12.6%), and 684 million yuan, respectively [4]. - Revenue is expected to grow from 14.63 billion yuan in 2023 to 18.59 billion yuan in 2027, with a compound annual growth rate of approximately 6.5% [5]. Profitability and Valuation - The company’s gross margin is projected to improve from 12.5% in 2023 to 13.4% in 2027, indicating a gradual recovery in profitability [12]. - The price-to-earnings (P/E) ratio is expected to decrease from 96 in 2023 to 20 in 2027, reflecting an anticipated recovery in earnings [13]. Market Position - The company is the only domestic player with full coverage of downstream terminal products, offering over 3,000 types of products across various applications [2]. - It has established partnerships with several Fortune 500 companies, enhancing its market presence and credibility [3].

Group 1 - The report highlights a significant downward revision in the US non-farm employment data for June, with a total adjustment of 90,000 jobs, primarily affecting government, leisure, and construction sectors, indicating potential economic instability due to tariffs [2] - The Federal Reserve is expected to maintain a hawkish stance on inflation, with a possibility of 1-2 rate cuts in the second half of the year as trade negotiations progress [3] - The market is anticipated to enter a new upward phase in the second half of the year, with a focus on cyclical sectors and emerging industries [4][5] Group 2 - The FDCA industry is projected to grow significantly due to increasing demand for PEF as a superior alternative to PET, with recommended investments in companies like Tongkun Co., New Fengming, and Zhenhai Refining [13] - The "anti-involution" policy is expected to continue, benefiting sectors like photovoltaic materials, with a focus on price elasticity in the supply chain [14][16] - The coal industry is seeing improved price expectations due to recent policy measures, with recommendations for investments in major coal companies [18] Group 3 - Qingdao Bank reported a 7.5% year-on-year increase in revenue for the first half of 2025, with a net profit growth of 16%, indicating strong performance and asset quality [20] - China Petroleum & Chemical Corporation (Sinopec) anticipates a significant decline in net profit for the first half of 2025, but maintains a "buy" rating based on long-term competitive advantages [23] - Huaneng International's second-quarter net profit increased by 50% year-on-year, driven by lower fuel costs and expansion in renewable energy [24] Group 4 - Ningde Times reported a 33.73% year-on-year increase in net profit for the second quarter of 2025, with strong market positioning in lithium batteries and new product developments [25] - Tencent is expected to see strong growth in core gaming and advertising revenues, with an upward revision of profit forecasts for 2025-2027 [26] - Meta Platforms exceeded revenue expectations in Q2 2025, with plans for increased investment in AI infrastructure [27]

2025 年 8 月 3 日 FY26Q2 指引相对平淡，自主芯片设计挑战和机遇并存 ——ARM（ARM.O）FY2026Q1 业绩点评 要点 事件： FY26Q1 业绩符合指引，FY26Q2 指引平淡。1）FY26Q1：FY26Q1 营 收 10.53 亿美元，YoY+12%，QoQ-15%，符合此前公司 10-11 亿美元指引区 间，市场预期 10.54 亿美元。授权收入 4.68 亿美元，YoY-1%；版税收入 5.85 亿美元，YoY+25%，系 Armv9 架构占比提升、Arm 芯片在数据中心的使用量 增长、CSS 芯片放量。盈利方面，FY26Q1 Non-GAAP EPS 0.35 美元， YoY-12.50%，符合此前公司 0.30~0.38 美元指引区间，市场预期 0.351 美元。 2）FY26Q2 利润指引偏弱：公司指引 FY26Q2 营收 10.1~11.1 亿美元，中值 对应 YoY+25.6%，QoQ+0.7%，市场预期 10.59 亿美元；指引 FY26Q2 Non-GAAP EPS 0.29~0.37 美元，中值较市场预期的 0.349 美元低 5.4%。公 司计划加大研发投入聚 ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [5]. Core Insights - The report highlights the recent outbreak of Chikungunya fever in Foshan, prompting a level III public health response, which has led to increased attention on related detection products [2][21]. - The report emphasizes the potential for rapid clinical data accumulation and expedited product approvals for companies offering Chikungunya detection solutions [23][25]. - It suggests focusing on companies that have launched Chikungunya detection solutions, including Da An Gene, Wanfu Biology, and others [2][25]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 2.95%, outperforming the CSI 300 index by 4.70 percentage points, ranking first among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index increased by 1.87%, surpassing the Hang Seng Index by 5.65 percentage points [1][15]. Company R&D Progress - Recent clinical applications include DB-1419 by Yimeng Bio and SHR-7782 by Heng Rui Medicine, both newly undertaken [28]. - Ongoing clinical trials include SYHX1901 and SHR-1905 by Shiyao Group and Heng Rui Medicine, respectively [28]. Important Company Announcements - Da An Gene and others have developed PCR-based detection solutions for Chikungunya fever, while BGI and Dian Diagnostics have introduced high-throughput sequencing solutions [23][25]. - Recent approvals include a medical device registration for digital X-ray systems by Xinhua Medical [27]. Financial Forecasts and Valuations - Key companies such as Heng Rui Medicine and Yuyue Medical are highlighted with projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2024-2026 [4]. - Heng Rui Medicine is rated "Accumulate" with a PE ratio forecast of 62 for 2024, decreasing to 49 in 2025 [4]. Industry Trends - The report notes a structural selection of investment opportunities based on payment channels within the pharmaceutical industry, focusing on hospital payments, out-of-pocket payments, and overseas payments [3][25]. - It identifies three key directions for investment: policy support for innovative drugs and devices, expansion of public demand for blood products and home medical devices, and an upward cycle for overseas sales [3][25].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [4][6]. Core Insights - The company has achieved significant cost reduction and efficiency improvements, with a revenue of 40.03 billion yuan in 2024, a year-on-year increase of 2.36%, and a net profit of 4.75 billion yuan, up 16.02% year-on-year [2][4]. - The company is advancing its nuclear medicine research, with the innovative nuclear drug INR102 entering a new phase of clinical trials [1][3]. - The company is focusing on digital transformation and innovation in traditional Chinese medicine, with multiple projects in various stages of development [3][4]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 40.03 billion yuan, with a net profit of 4.75 billion yuan, marking a historical high [2]. - The operating cash flow reached 4.30 billion yuan, reflecting a year-on-year increase of 22.68% [2]. - The company’s gross margin improved to 27.9% in 2024, with a net profit margin of 11.9% [12]. Research and Development - The company is actively pursuing both short-term and long-term projects in traditional Chinese medicine and innovative drugs, with several products in various clinical trial phases [3]. - The nuclear medicine segment is a key focus, with two innovative nuclear drugs entering clinical trials [3]. Profit Forecast and Valuation - The profit forecast for 2025 and 2026 has been slightly adjusted upwards to 5.27 billion yuan and 5.85 billion yuan, respectively [4]. - The current stock price corresponds to a price-to-earnings ratio of 19 for 2025, indicating a favorable valuation [4].

Investment Rating - The report maintains a "Buy" rating for the agricultural, forestry, animal husbandry, and fishery sector, indicating an expected investment return exceeding 15% over the next 6-12 months [5]. Core Insights - The report highlights a strong rebound in meat and poultry prices due to increased stocking and the arrival of the consumption peak season [1][2]. - The pig price has shown a week-on-week increase of 1.27%, with the average price reaching 14.33 yuan/kg as of August 1 [23]. - The white feathered chicken price rose by 1.94% to 6.83 yuan/kg, while chick prices surged by 33.16% to 2.57 yuan/bird, driven by limited market supply and increased stocking enthusiasm among farmers [2][35]. - Corn and wheat prices have decreased slightly, while soybean meal prices have increased, indicating mixed trends in feed costs [3][50]. Summary by Sections 1. Market Overview - The agricultural sector underperformed against the broader market, with the agricultural index declining by 2.97% [14]. - The animal husbandry segment saw a significant drop, particularly in pig farming, which fell by 4.63% [14]. 2. Key Data Tracking - Pig prices increased to 14.33 yuan/kg, while the average weight of pigs at slaughter was 127.98 kg, reflecting a slight decrease [22][23]. - The white feathered chicken price reached 6.83 yuan/kg, and chick prices rose significantly, indicating a recovery in the poultry market [35][21]. - Yellow chicken prices improved due to seasonal demand, with medium-speed chicken prices increasing by 8.33% to 5.46 yuan/jin [45]. 3. Investment Recommendations - The report recommends focusing on the pig farming sector, anticipating a favorable supply-demand balance in August, with key companies to watch including Muyuan Foods, Wens Foodstuff Group, and Juxing Agriculture [4][71]. - For the feed and veterinary sectors, companies like Haida Group and Reap Bio are highlighted due to rising demand from increased pig stocks [4][71]. - In the planting chain, companies such as Suqian Agricultural Development and Beidahuang are recommended as grain prices are expected to rise [4][71]. - The pet food sector is also noted for growth potential, with companies like Guibao Pet and Zhongchong Co. being highlighted [4][74].

Investment Rating - The report maintains a "Buy" rating for the agricultural, forestry, animal husbandry, and fishery sector [5] Core Insights - The report indicates a strong rebound in meat and poultry prices due to increased stocking and the arrival of the consumption peak season [1][2] - The pig price has shown a week-on-week increase of 1.27%, with the average price reaching 14.33 yuan/kg as of August 1 [23] - The white feather broiler price has risen by 1.94% to 6.83 yuan/kg, while chick prices surged by 33.16% to 2.57 yuan/bird [33] - Corn and wheat prices have decreased slightly, with corn averaging 2402.75 yuan/ton (down 0.21%) and wheat at 2440.5 yuan/ton (down 0.17%) [48] Summary by Sections 1. Market Review - The agricultural, forestry, and fishery sector underperformed the market, with a decline of 2.97% in the sector index [14] - The animal husbandry segment saw a significant drop of 4.63% [14] 2. Key Data Tracking 2.1 Swine - The average weight of market pigs is 127.98 kg, down 0.5 kg week-on-week, with a frozen meat inventory rate of 14.54% [23] 2.2 White Feather Broilers - The market is experiencing limited supply, leading to price increases for both broilers and chicks [33] 2.3 Yellow Feather Broilers - Yellow chicken prices have increased by 8.33% to 5.46 yuan/jin, driven by improved supply-demand dynamics during the summer [43] 2.4 Feed Sector - The report notes a slight decrease in corn and wheat prices, while soybean meal prices have increased by 0.49% to 2977.71 yuan/ton [48] 3. Investment Recommendations - The report recommends focusing on the swine breeding sector, highlighting companies such as Muyuan Foods, Wens Foodstuffs, and Juxing Agriculture [4] - It also suggests monitoring the feed and animal health sectors, particularly Haida Group and Reap Bio [4] - In the planting chain, companies like Suqian Agricultural Development and Beidahuang are recommended due to favorable grain price trends [4] - The pet food sector is also highlighted for its growth potential, with recommendations for companies like Guibao Pet and Zhongchong Co [4]

2025 年 8 月 3 日 行业研究 政治局会议强调"反内卷"及"科技创新"，关注龙头白马及国产替代 ——基础化工行业周报（20250728-20250803） 要点 中共中央政治局召开会议，强调"产能治理"及"科技创新"。 7 月 30 日， 中共中央政治局召开会议，会议分析研究当前经济形势，部署下半年经济工 作。会议认为，今年以来，我国经济运行稳中有进，高质量发展取得新成 效。主要经济指标表现良好，新质生产力积极发展，改革开放不断深化，重 点领域风险有力有效防范化解，民生兜底保障进一步加强，我国经济展现强 大活力和韧性。但同时，会议指出，当前我国经济运行依然面临不少风险挑 战。此外，会议指出，要坚定不移深化改革。坚持以科技创新引领新质生产 力发展，加快培育具有国际竞争力的新兴支柱产业，推动科技创新和产业创 新深度融合发展。纵深推进全国统一大市场建设，推动市场竞争秩序持续优 化。依法依规治理企业无序竞争。推进重点行业产能治理。 新一轮供给侧改革来临，利好化工细分子行业龙头。近期各有关部门和部分 地方政府陆续发布重点行业产能治理、老旧装置摸底评估相关政策与文件。 伴随着"反内卷"相关政策的陆续出台，老旧产能 ...